… sarcopenia is its involvement in the pathogenesis of disease progression as well as in
therapeutic … , emerging evidence has confirmed that antifibrotic therapy (AFT) reduces the risks of …

… of probable sarcopenia was 19.6% (10 cases). No differences in regards to antifibrotic treatment
… side effects were observed between patients with and without sarcopenia at follow-up. …

… On the other hand, there were no significant differences in comorbidities or treatments (antifibrotic
drugs or corticosteroids) between the groups. Similarly, there were no significant …

… Our results found that sarcopenia patients had a 1.3-fold statistical increase of developing
… when compared with subjects without sarcopenia. The above-mentioned association was …

… antifibrotic therapy, some patients with IPF may live longer (11, 12). Considering the adverse
outcomes that sarcopenia can cause in patients … awareness of sarcopenia as a comorbidity. …

… of sarcopenia and cachexia, which are often found in patients … mortality in patients with
IPF receiving antifibrotic therapy. … were found to increase with lower BMI in patients with IPF. …

… oxygen therapy, and medications (steroids and antifibrotic drugs) were collected from the
electronic medical records. The medications included not only the drugs for the treatment of IPF…

… decline independently of BMI and had a greater effect in patients with > 5% weight loss 8 . In
… IPF patients under anti-fibrotic therapy had skeletal muscle loss and that sarcopenia was a …

… , it has been reported that sarcopenia obesity is not a risk for mortality in CKD patients [24].
In … the general population and CKD patients, and the study may include sarcopenia obesity. …

… In the comparison of PROs between the sarcopenic and non-sarcopenic patients with 5 …
and sarcopenia in patients with idiopathic 14 pulmonary fibrosis receiving antifibrotic therapy, …